NCT00825643View on ClinicalTrials.gov

Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes

CompletedOBSERVATIONAL
Enrollment

18,481

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

insulin detemir

Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation

Trial Locations (9)

28033

Novo Nordisk Investigational Site, Madrid

34335

Novo Nordisk Investigational Site, Istanbul

44425

Novo Nordisk Investigational Site, Kfar Saba

55127

Novo Nordisk Investigational Site, Mainz

100004

Novo Nordisk Investigational Site, Beijing

L4W 4XI

Novo Nordisk Investigational Site, Mississauga

00144

Novo Nordisk Investigational Site, Rome

PL-02-274

Novo Nordisk Investigational Site, Warsaw

2780-730

Novo Nordisk Investigational Site, Paço de Arcos

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00825643 - Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes | Biotech Hunter | Biotech Hunter